Cytek Biosciences, Inc. — Director's Dealing 2021

Jul 23, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Cytek BioSciences, Inc. (CTKB)
CIK: 0001831915
Period of Report: 2021-07-22

Reporting Person: Jiang Wenbin (Director, President and CEO)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	7847710	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (2666600)		Indirect
Stock Option (Right to Buy)	$0.25	2027-06-28	Common Stock (66665)		Direct
Stock Option (Right to Buy)	$0.92	2030-07-24	Common Stock (106664)		Direct

Footnotes

F1: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.

F2: These securities are held by WYTJ LLC for which the Reporting Person is a Manager. The Reporting Person disclaims beneficial ownership of the shares held by WYTJ LLC except to the extent of his pecuniary interest therein, if any.

F3: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on July 24, 2021; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years.